Your session is about to expire
← Back to Search
18F-AraG Imaging for Non-Small Cell Lung Cancer
Study Summary
This trial is studying how a new T-cell imaging agent moves around the body in patients with non-small cell lung cancer who are getting immunotherapy with or without radiation therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current status of 18F-AraG's approval from the FDA?
"Analyses conducted by Power suggest that 18F-AraG has a safety rating of 1 as it is currently undergoing Phase 1 clinical trials, which means there is minimal evidence regarding its efficacy and safety."
Are any further participants currently being recruited for this experiment?
"Clinicaltrials.gov attests to the fact that this medical research project is still seeking participants; its initial posting was on July 16th, 2019 and it has been modified most recently on May 12th 2022."
How many participants are there in this clinical investigation?
"Yes, the clinical trial data present on clinicaltrials.gov confirms that this study is actively recruiting participants. The experimental protocol was first posted on July 16th 2019 and last modified on May 12th 2022; 2 candidates are required to be recruited from a single facility."
Share this study with friends
Copy Link
Messenger